Explore the vast range of titles available.

The technological revolution in vaccination — from the empirical approach pioneered by Jenner and Pasteur to the recent developments in structural and reverse vaccinology, combined with synthetic biology — promises great hope for the development of safer and more effective vaccines against all infectious diseases. Vaccination, which is the most effective medical intervention that has ever been introduced, originated from the observation that individuals who survived a plague or smallpox would not get the disease twice. To mimic the protective effects of natural infection, Jenner — and later Pasteur — inoculated individuals with attenuated or killed disease-causing agents. This empirical approach inspired a century of vaccine development and the effective prophylaxis of many infectious diseases. From the 1980s, several waves of new technologies have enabled the development of novel vaccines that would not have been possible using the empirical approach. The technological revolution in the field of vaccination is now continuing, and it is delivering novel and safer vaccines. In this Timeline article, we provide our views on the transition from empiricism to rational vaccine design.

\"Learn more about the history and success rate of vaccines as well as their limitations, explore the challenges the medical community faces, and discover what vaccines are currently in development.\"--Provided by publisher.

Vaccines have a history that started late in the 18th century. From the late 19th century, vaccines could be developed in the laboratory. However, in the 20th century, it became possible to develop vaccines based on immunologie markers. In the 21st century, molecular biology permits vaccine development that was not possible before.

\"An intelligent and compelling examination of the science of immunity, the public policy implications of vaccine denial, and the real-world outcomes of failing to vaccinate. If you have a child in school, you may have heard stories of long-dormant diseases suddenly reappearing--cases of measles, mumps, rubella, and whooping cough cropping up everywhere from elementary schools to Ivy League universities. How does a small group of people's failure to vaccinate have the potential to affect future generations? Are we at a turning point in medical history, where deadly diseases, once dormant, flourish anew? Will our children face summers of abandoned swimming pools due to polio outbreaks just like our great-grandparents did? Pioneering medical researcher Michael Kinch tells the remarkable story of vaccine-preventable infectious diseases in [this book], which explains how the science of immunity actually works and places immunology within the context of its social and political implications. While detailing the history of vaccine invention, from the steppes of Mongolia to the serendipitous connection between cowpox and smallpox, Kinch reveals the ominous reality that our victories against vaccine-preventable diseases are not permanent--and could easily be undone. ... Between Hope and Fear illuminates the fascinating intersection of science, technology, and disease that has helped eradicate many of the deadliest plagues known to man.\"-- Jacket.

The FDA recently authorized two mRNA vaccines for the prevention of Covid-19. Clearance of this hurdle represents the most recent in a series of advances in the realm of viral vaccines, each building on the last and each with a compelling record of disease prevention.

\"A vibrant cultural history investigating the tangled and complex history of pandemics and vaccines, by bestselling author and historian Simon Schama\"--Dust jacket flap.

Although viruses and bacteria have been known as agents of diseases since 1546, 250 years went by until the first vaccines against these pathogens were developed (1796 and 1800s). In contrast, Malaria, which is a protozoan-neglected disease, has been known since the 5th century BCE and, despite 2,500 years having passed since then, no human vaccine has yet been licensed for Malaria. Additionally, no modern human vaccine is currently licensed against Visceral or Cutaneous leishmaniasis. Vaccination against Malaria evolved from the inoculation of irradiated sporozoites through the bite of Anopheles mosquitoes in 1930's, which failed to give protection, to the use of controlled human Malaria infection (CHMI) provoked by live sporozoites of and curtailed with specific chemotherapy since 1940's. Although the use of CHMI for vaccination was relatively efficacious, it has some ethical limitations and was substituted by the use of injected recombinant vaccines expressing the main antigens of the parasite cycle, starting in 1980. Pre-erythrocytic (PEV), Blood stage (BSV), transmission-blocking (TBV), antitoxic (AT), and pregnancy-associated Malaria vaccines are under development. Currently, the RTS,S-PEV vaccine, based on the circumsporozoite protein, is the only one that has arrived at the Phase III trial stage. The \"R\" stands for the central repeat region of circumsporozoite protein (CSP); the \"T\" for the T-cell epitopes of the CSP; and the \" \" for hepatitis B surface antigen (HBsAg). In Africa, this latter vaccine achieved only 36.7% vaccine efficacy (VE) in 5-7 years old children and was associated with an increase in clinical cases in one assay. Therefore, in spite of 35 years of research, there is no currently licensed vaccine against Malaria. In contrast, more progress has been achieved regarding prevention of leishmaniasis by vaccine, which also started with the use of live vaccines. For ethical reasons, these were substituted by second-generation subunit or recombinant DNA and protein vaccines. Currently, there is one live vaccine for humans licensed in Uzbekistan, and four licensed veterinary vaccines against visceral leishmaniasis: Leishmune® (76-80% VE) and CaniLeish® (68.4% VE), which give protection against strong endpoints (severe disease and deaths under natural conditions), and, under less severe endpoints (parasitologically and PCR-positive cases), Leishtec® developed 71.4% VE in a low infective pressure area but only 35.7% VE and transient protection in a high infective pressure area, while Letifend® promoted 72% VE. A human recombinant vaccine based on the Nucleoside hydrolase NH36 of , the main antigen of the Leishmune® vaccine, and the sterol 24-c-methyltransferase (SMT) from has reached the Phase I clinical trial phase but has not yet been licensed against the disease. This review describes the history of vaccine development and is focused on licensed formulations that have been used in preventive medicine. Special attention has been given to the delay in the development and licensing of human vaccines against Protozoan infections, which show high incidence worldwide and still remain severe threats to Public Health.

Hundreds of scientists had worked on mRNA vaccines for decades before the coronavirus pandemic brought a breakthrough. Hundreds of scientists had worked on mRNA vaccines for decades before the coronavirus pandemic brought a breakthrough.